{
    "ticker": "CYCCP",
    "name": "Cyclacel Pharmaceuticals, Inc.",
    "description": "Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative medicines for the treatment of cancer and other diseases. Founded in 1996 and headquartered in Durham, North Carolina, Cyclacel is dedicated to advancing its proprietary drug candidates that target key pathways in cancer biology. The company is particularly known for its work with cell cycle and transcriptional regulation, with its lead product candidate, CYC065, an oral CDK2/9 inhibitor, currently undergoing clinical trials for various hematological malignancies and solid tumors. Cyclacel's mission is to deliver compelling treatment options to patients suffering from cancer, leveraging its strong scientific foundation and expertise in drug development. Their pipeline includes several promising candidates designed to overcome resistance mechanisms in cancer therapy, highlighting their commitment to addressing unmet medical needs in oncology. Cyclacel continues to engage in partnerships and collaborations with leading academic institutions and industry players to enhance its research capabilities and accelerate the development of its product candidates. The company is also exploring new therapeutic areas beyond oncology, which may expand its portfolio and impact.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "1996",
    "website": "http://www.cyclacel.com",
    "ceo": "Spencer K. R. H. G. M. L. S. G. H. M. E. A. D.",
    "social_media": {
        "twitter": "https://twitter.com/Cyclacel",
        "linkedin": "https://www.linkedin.com/company/cyclacel-pharmaceuticals/"
    },
    "investor_relations": "http://ir.cyclacel.com",
    "key_executives": [
        {
            "name": "Spencer K. R. H. G. M. L. S. G. H. M. E. A. D.",
            "position": "CEO"
        },
        {
            "name": "James F. D. H. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "CYC065",
                "CYC140"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cyclacel Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Cyclacel Pharmaceuticals, Inc., a leader in developing innovative cancer therapies targeting key biological pathways to improve patient outcomes.",
        "keywords": [
            "Cyclacel",
            "Cancer Treatment",
            "CDK Inhibitors",
            "Biopharmaceuticals",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Cyclacel known for?",
            "answer": "Cyclacel is known for its development of innovative cancer therapies, particularly targeting cell cycle regulation."
        },
        {
            "question": "Who is the CEO of Cyclacel?",
            "answer": "Spencer K. R. H. G. M. L. S. G. H. M. E. A. D. is the CEO of Cyclacel Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Cyclacel headquartered?",
            "answer": "Cyclacel is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are Cyclacel's main products?",
            "answer": "Cyclacel's main products include CYC065 and CYC140, which are in development for cancer treatment."
        },
        {
            "question": "When was Cyclacel founded?",
            "answer": "Cyclacel was founded in 1996."
        }
    ],
    "competitors": [
        "CLVS",
        "NTRP",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "BMY"
    ]
}